In the pharmaceutical industry, some amorphous drugs have been shown to offer higher bioavailability than their crystalline counterparts as a result of the higher solubility of the amorphous phase. However, certain compounds can undergo precipitation in their amorphous form in vivo, and can then decrease mutual bioavailability if administered together.